Natural killer cell lines in tumor immunotherapy (Q37998371)

26 August 2017

Natural killer cell lines in tumor immunotherapy (English)

1 reference

26 August 2017

1 reference

1 reference

Min Cheng

1

1 reference

26 August 2017

Jian Zhang

2

1 reference

26 August 2017

Wen Jiang

3

1 reference

26 August 2017

Yongyan Chen

4

1 reference

26 August 2017

Zhigang Tian

5

1 reference

26 August 2017

31 March 2012

1 reference

26 August 2017

Frontiers of medicine

1 reference

26 August 2017

6

1 reference

26 August 2017

1

1 reference

26 August 2017

56-66

1 reference

https://scigraph.springernature.com/pub.10.1007/s11684-012-0177-7

26 August 2017

0 references

cites work

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

„Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Natural killer cell developmental pathways: a question of balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

The trafficking of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

The biology of human natural killer-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

NK cell and DC interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

The biology of the human natural killer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Natural killer cells, viruses and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

The biology of natural killer cells in cancer, infection, and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Natural killer cell-based immunotherapy in cancer: current insights and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Activation, coactivation, and costimulation of resting human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Natural killer cell memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Prospects for the use of NK cells in immunotherapy of human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Cytokines in cancer immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Interleukin-2, interleukin-15, and their roles in human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Different checkpoints in human NK-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Biology of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Interleukin-2 and interleukin-15: immunotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Artificial cells for the development of cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

New aspects of natural-killer-cell surveillance and therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3epsilon+, CD56+ phenotype and associated with the Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Natural killer cell-based immunotherapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Interleukin 15: biology and relevance to human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Chimeric antigen receptors for the retargeting of cytotoxic effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Proteomic analysis of human NK-92 cells after NK cell-mediated cytotoxicity against K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

REGULATION OF FAS AND FAS-LIGAND EXPRESSION IN NK CELLS BY CYTOKINES AND THE INVOLVEMENT OF FAS-LIGAND IN NK/LAK CELL-MEDIATED CYTOTOXICITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

REGULATION OF APO-2 LIGAND/TRAIL EXPRESSION IN NK CELLS—INVOLVEMENT IN NK CELL-MEDIATED CYTOTOXICITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-012-0177-7

Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

21 January 2018

1 reference

12 December 2020

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

1 reference

12 December 2020

TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells).

1 reference

12 December 2020

Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells

1 reference

12 December 2020

Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer

1 reference

12 December 2020

Differentiation of human NK cells into NK1 and NK2 subsets.

1 reference

12 December 2020

Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

1 reference

12 December 2020

Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line

1 reference

12 December 2020

Autologous natural killer cell therapy for human recurrent malignant glioma.

1 reference

12 December 2020

A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.

1 reference

12 December 2020

Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes

1 reference

12 December 2020

Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer

1 reference

12 December 2020

CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell bas

1 reference

12 December 2020

Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells

1 reference

12 December 2020

Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line.

1 reference

12 December 2020

Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer

1 reference

12 December 2020

Interleukin-2 in the treatment of renal cancer

1 reference

12 December 2020

Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma

1 reference

12 December 2020

Antileukemia activity of a natural killer cell line against human leukemias

1 reference

12 December 2020

Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy

1 reference

12 December 2020

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

1 reference

12 December 2020

Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer

1 reference

12 December 2020

Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas

1 reference

12 December 2020

Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection.

1 reference

12 December 2020

Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors.

1 reference

12 December 2020

Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line

1 reference

12 December 2020

Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.

1 reference

12 December 2020

Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia

1 reference

12 December 2020

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells

1 reference

12 December 2020

Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT

1 reference

12 December 2020

Tumor-specific T-bodies: towards clinical application

1 reference

12 December 2020

Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.

1 reference

12 December 2020

Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells

1 reference

12 December 2020

Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy.

1 reference

12 December 2020

In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells

1 reference

12 December 2020

Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy.

1 reference

12 December 2020

10.1007/S11684-012-0177-7

Identifiers

DOI

1 reference

26 August 2017

1 reference